Lowering the bar on Alzheimer’s drugs: STAT op-ed takes industry-friendly line, without disclosing author’s pharma ties

A recent op-ed published Monday in STAT insists that proposed FDA guidance for Alzheimer’s drug development is “good news” that “removes unnecessary barriers” to bring new medications to market. If the guidance is finalized, pharmaceutical companies would no longer have to prove that their drugs impact the endpoints of “cognition and function” when tested on … Continue reading Lowering the bar on Alzheimer’s drugs: STAT op-ed takes industry-friendly line, without disclosing author’s pharma ties